Introduction {#S0001}
============

Drug-eluting stents (DES) have become the most widely used coronary stents in clinical practice \[[@CIT0001]\]. A number of clinical trials have verified the benefits of DES in reducing the rates of in-stent restenosis or target lesion revascularization (TLR) compared with bare metal stents in unselected patients with coronary artery diseases \[[@CIT0002]--[@CIT0004]\]. Patients with diabetes are especially prone to restenosis after stenting, making DES preferable to bare-metal stents in this patient population \[[@CIT0005]\]. Currently, diabetic patients make up approximately 25% of those treated with DES \[[@CIT0006]\]. A pooled analysis from the SPIRIT and COMPARE trials showed an interaction between diabetes mellitus and stent type on clinical outcomes \[[@CIT0007]\]. Several meta-analyses have previously reported the efficacy and safety of the first-generation sirolimus-eluting stents (SES) versus bare-metal stents \[[@CIT0008]\] or the first-generation paclitaxel-eluting stents (PES) \[[@CIT0009]\] in patients with diabetes mellitus. However, it remains unclear whether the second-generation DES (e.g. everolimus-eluting stents (EES) or zotarolimus-eluting stents (ZES)) and the first-generation DES are able to provide a similarly beneficial effect in these specific subjects.

Therefore, here we performed a meta-analysis of randomized controlled trials (RCTs) comparing the second- versus first-generation DES to elucidate the clinical utility of various DES in patients with diabetes mellitus.

Material and methods {#S0002}
====================

Search strategy {#S20003}
---------------

Eligible studies were identified through a computerized literature search of PubMed, EMBASE, and Cochrane databases until July 2013. Complex search strategies were formulated using the following text words: *everolimus-eluting stent, zotarolimus-eluting stent, second-generation eluting stent, sirolimus-eluting stent, paclitaxel-eluting stent, first-generation eluting stent, diabetes, diabetic, human, random*. An extensive search of the ISI Web of Science database using cross-references from the eligible articles and relevant reviews was also conducted. The search was restricted to English-language literature.

Selection criteria {#S20004}
------------------

Randomized controlled trials involving head-to-head comparison of clinical outcomes of second-generation DES (EES or ZES) versus first-generation DES (SES or PES) in patients with a diagnosis of diabetes were eligible for the meta-analysis. Moreover, more than 6-month follow-up data were required to be reported. We excluded studies that compared clinical utility of DES with BMS, and post-hoc analyses of RCTs were also excluded.

Study enrollment and data extraction {#S20005}
------------------------------------

Two investigators independently reviewed all citations to identify the eligible studies and used a standardized form to extract the data including characteristics of study, participant, and procedure characteristics as well as follow-up duration from each study. Clinical outcomes of all-cause death, stent-thrombosis, reinfarction, and TLR were also recorded. The reviewers resolved differences through consensus, and the principal investigators resolved any disagreements. Quality of eligible articles was evaluated with a quality scale (a 5-point scale) by Jadad *et al*. \[[@CIT0010]\].

Statistical analysis {#S20006}
--------------------

The Mantel-Haenszel method for random effects was used to investigate the combined results of clinical endpoints in individual studies. Risk ratios (RR) with 95% confidence intervals (CI) for all results were computed as summary estimates.

Statistical heterogeneities across studies were quantified using the *I*^2^ statistic \[[@CIT0011]\]. To investigate the clinical factors impacting clinical outcomes, we stratified and analyzed data on TLR and stent thrombosis according to the type of DES, stent length, dual antiplatelet therapy (DAPT) duration, and follow-up period. Sensitivity analyses were conducted to examine the robustness of the effect by alternatively using a fixed-effect model. We qualitatively assessed publication bias using the funnel plot method. The significance level was set at *p* \< 0.05. Analyses were performed with the RevMan 5.1 software (The Cochrane Collaboration, Copenhagen, Denmark). The meta-analysis was prepared according to the PRISMA guidelines \[[@CIT0012]\].

Results {#S0007}
=======

Selected studies and characteristics {#S20008}
------------------------------------

The initial electronic database search identified 1773 items. Of them 10 articles \[[@CIT0013]--[@CIT0022]\] were eligible for inclusion in the analysis, and no additional relevant study was identified from the references and citations of the eligible articles and review articles ([Figure 1](#F0001){ref-type="fig"}).

![Flowchart of selection of studies for inclusion\
BMS -- bare-metal stents, DES -- drug-eluting stents, PES -- paclitaxel-eluting stents, RCTs -- randomized controlled trials, SES -- sirolimus-eluting stent.](AMS-10-22702-g001){#F0001}

[Table I](#T0001){ref-type="table"} summarizes the design features of the individual studies. A total of 4503 diabetic patients, 2350 being randomly allocated to the second-generation DES implantation group and 2153 to the first-generation DES implantation group, were included for analysis. They received DAPT for no less than 6 to 12 months according to current practice guidelines or study design protocol. The mean age of patients ranged from 62.9 to 68.1 years, and the percentage of males was from 57% to 74.5%. Total stent length per patient was less than 30.0 mm except for the ZEST Diabetic study (37.6 mm) \[[@CIT0020]\] and the mean diameter of reference vessels ranged from 2.67 mm to 3.20 mm. Among the 10 included trials, 7 and 8 reported a lower percentage of insulin use \[[@CIT0013], [@CIT0014], [@CIT0016]--[@CIT0018], [@CIT0021], [@CIT0022]\] and glycoprotein IIb/IIIa inhibitor use \[[@CIT0013]--[@CIT0015], [@CIT0017]--[@CIT0021]\], respectively. In addition, of these trials, one reported 10-month follow-up data \[[@CIT0017]\]; 4 reported 12-month data \[[@CIT0013], [@CIT0015], [@CIT0016], [@CIT0021]\]; 2 reported 18-month results \[[@CIT0014], [@CIT0019]\]; and 3 reported ≥ 24-month findings \[[@CIT0018], [@CIT0020], [@CIT0022]\]. The level of evidence for each article was graded with a score of 3 to 4 according to the Jadad quality score ([Table I](#T0001){ref-type="table"}).

###### 

Baseline characteristics of randomized controlled trials included in the meta-analysis

  Study name, year             Comparisons           No. enrolled   Mean age \[years\]   Male (%)   Current smoker (%)   Insulin use (%)   ACS (%)   Target vessel, LAD/LCX/RCA (%)   Reference diameter \[mm\]   Stent length\[mm\]   DAPT duration\[m\]   Use of GP IIb/IIIa inhibitors (%)   Follow-up \[m\]   Jaded score
  ---------------------------- --------------------- -------------- -------------------- ---------- -------------------- ----------------- --------- -------------------------------- --------------------------- -------------------- -------------------- ----------------------------------- ----------------- -------------
  ESSENCE-DIABETES, 2011       EES vs. SES           149/151        63.3                 59         24                   15                41.7      60/15.3/24.7                     2.77                        28.7                 12                   3                                   12                4
  ISAR-TEST-4 diabetic, 2013   EES vs. SES           184/193        68.1                 74.5       14.2                 32.5              40.3      45/27/28                         --                          --                   6                    --                                  36                4
  SORT OUT IV, 2012            EES vs. SES           194/196        63.6                 74.4       26                   32.1              34.4      38.5/25.2/33.3                   3.2                         29.6                 12                   17.1                                18                3
  SPIRIT IV, 2010              EES vs. PES           786/399        63.4                 63.3       18.2                 --                29.1      39.6/26.9/33.6                   2.74                        21.75                12                   18.3                                12                4
  SPIRIT V Diabetic, 2012      EES vs. PES           218/106        65.5                 69         16.3                 28.5              52.4      42.7/29.3/28                     --                          --                   6                    --                                  12                3
  Naples-Diabetes, 2011        ZES vs. SES vs. PES   75/76/75       64                   57         18.6                 27                14.1      61.5/23.2/21.4                   2.84                        25                   6--12                31.7                                36                3
  ZEST Diabetic, 2012          ZES vs. SES vs. PES   268/247/245    62.9                 60.8       24.9                 --                52.9      49.4/21.6/29                     --                          37.6                 12                   2.2                                 24                3
  SORT OUT III, 2011           ZES vs. SES           169/168        66                   71         29                   --                44.5      40/26/31                         --                          24                   12                   22                                  18                4
  DiabeDES III, 2011           ZES vs. SES           66/61          63.2                 72.8       34.5                 27.3              38.6      41/15.5/43.5                     2.86                        21.4                 12                   23.6                                10                4
  ENDEAVOR IV, 2009            ZES vs. PES           241/236        64                   60.6       --                   43.2              52.5      39.5/29/31.5                     2.67                        20.8                 12                   24.5                                12                4

ACS -- acute coronary syndrome, DAPT -- dual antiplatelet therapy, EES -- everolimus-eluting stents, LAD -- left anterior descending artery, LCX -- left circumflex artery, NA -- not available, PES -- paclitaxel-eluting stents, RCA -- right coronary artery, STEMI -- ST-segment elevation myocardial infarction, TIMI -- thrombolysis in myocardial infarction, SES -- sirolimus-eluting stents, ZES -- zotarolimus-eluting stent

Meta-analysis for stent thrombosis {#S20009}
----------------------------------

The pooling analyses showed that there was no significant difference in the risk of probable/definite stent thrombosis between the second-generation EES and the first-generation SES or PES (EES vs. SES: RR = 0.44, *p* = 0.10, *I*^2^ =0%; EES vs. PES: RR = 0.42, *p* = 0.24, *I*^2^ = 20%), whereas EES presented a significant benefit compared with the overall first-generation DES (RR = 0.46; *p* = 0.03; [Table II](#T0002){ref-type="table"}). In contrast, the second-generation ZES markedly increased the incidence of adverse outcome compared with the first-generation SES (RR = 4.47, 95% CI: 1.13--17.64; *p* = 0.03; *I*^2^ = 0%, [Figure 2](#F0002){ref-type="fig"}), and the unfavorable effect of ZES was also observed when compared with the overall first-generation DES (RR = 2.91, 95% CI: 1.14--7.43, *p* = 0.03, [Table II](#T0002){ref-type="table"}). In addition, the neutral inter-group effect was observed consistently in other subgroups, regardless of implanted stent length, DAPT duration, and follow-up duration (all *p* \> 0.10, [Table II](#T0002){ref-type="table"}).

![Forest plot of risk ratios in stent thrombosis in patients treated with second-generation DES compared with first-generation DES\
CI -- confidence intervals, DES -- drug-eluting stents, MH -- Mantel-Haenszel method.](AMS-10-22702-g002){#F0002}

###### 

Subgroup analyses based on the data on TLR and stent thrombosis

  Factors                      TLR   Stent thrombosis                                      
  ---------------------------- ----- -------------------- ------- --- -------------------- ------
  EES implantation             5     0.84 (0.52, 1.34)    0.46    5   0.46 (0.22, 0.9)     0.03
  ZES implantation             5     2.37 (1.24, 4.52)    0.009   5   2.91 (1.14, 7.43)    0.03
  Stent length \< 25.0 mm      4     1.86 (0.69, 5.00)    0.22    4   1.40 (0.45, 4.35)    0.56
  Stent length ≥ 25.0 mm       4     1.07 (0.39, 2.98)    0.90    4   1.34 (0.45, 3.97)    0.60
  DAPT duration \< 12 months   3     1.93 (0.86, 4.34)    0.11    3   0.89 (0.17, 4.63)    0.89
  DAPT duration = 12 months    7     1.21 (0.62, 2.34)    0.57    7   1.08 (0.55, 2.12)    0.83
  10-month follow-up           1     2.78 (0.12, 66.88)   0.52    1   2.78 (0.12, 66.88)   0.53
  ≤ 12-month follow-up         5     1.10 (0.72, 1.68)    0.65    5   0.79 (0.32, 1.93)    0.61
  \> 12-month follow-up        5     1.93 (0.91, 4.08)    0.09    5   1.27 (0.49, 3.29)    0.62

CI -- confidence interval, DAPT -- dual antiplatelet therapy, EES -- everolimus-eluting stents, RR -- risk ratio, TLR -- target lesion revascularization, ZES -- zotarolimus-eluting stent

Meta-analysis for target lesion revascularization {#S20010}
-------------------------------------------------

A benefit associated with EES implantation on reducing the incidence of TLR was not observed (RR = 0.62, *p* = 0.16; *I*^2^ = 37%, [Figure 3](#F0003){ref-type="fig"}). However, the use of ZES significantly increased the need for repeat revascularization in comparison with the SES (RR = 6.79, 95% CI: 3.19--14.48; *p* \< 0.01; *I*^2^ = 0%, [Figure 3](#F0003){ref-type="fig"}) or the overall first-generation DES (RR = 2.37, 95% CI: 1.24--4.52; *p* = 0.009, [Table II](#T0002){ref-type="table"}). Additionally, the inferiority of the second-generation DES seemed to be marked in diabetic patients with follow-up duration of more than 12 months (*p* = 0.09, [Table II](#T0002){ref-type="table"}). Nevertheless, compared with the first generation PES, both EES and ZES did not show a significant difference in the rate of TLR (both *p* \> 0.10, [Figure 3](#F0003){ref-type="fig"}).

![Forest plot of risk ratios in target lesion revascularization in patients treated with second-generation DES compared with first-generation DES. Abbreviations as in [Figure 2](#F0002){ref-type="fig"}](AMS-10-22702-g003){#F0003}

Meta-analysis for recurrent myocardial infarction and all-cause death {#S20011}
---------------------------------------------------------------------

The second-generation EES did not present a benefit in reducing the risk of recurrent myocardial infarction compared with the first-generation SES (RR = 0.44, *p* = 0.19; *I*^2^ = 32%), but showed a beneficial tendency compared with PES (RR = 0.58, 95% CI 0.31--1.06; *p* = 0.08; *I*^2^ = 16%, [Figure 4](#F0004){ref-type="fig"}). However, there was no statistically significant difference between ZES and SES or PES (ZES vs. SES: RR = 2.65, *p* = 0.13; *I*^2^ = 42%; ZES vs. PES: RR = 0.93, *p* = 0.81; *I*^2^ = 16%; [Figure 4](#F0004){ref-type="fig"}). In addition, the use of EES was associated with reduced incidence of all-cause death compared with SES in patients with diabetes (RR = 0.58, 95% CI: 0.37--0.90; *p* = 0.01; *I*^2^ = 0%; [Figure 5](#F0005){ref-type="fig"}). Except for this, no significant inter-group differences were found (all *p* \> 0.10, [Figure 5](#F0005){ref-type="fig"}).

![Forest plot of risk ratios in reinfarction in patients treated with second-generation DES compared with first-generation DES. Abbreviations as in [Figure 2](#F0002){ref-type="fig"}](AMS-10-22702-g004){#F0004}

![Forest plot of risk ratios in all-cause death in patients treated with second-generation DES compared with first-generation DES. Abbreviations as in [Figure 2](#F0002){ref-type="fig"}](AMS-10-22702-g005){#F0005}

Sensitivity analysis and publication bias {#S20012}
-----------------------------------------

In the sensitivity analyses, after alternatively using the fixed-effect model, the pooled estimate of ZES versus SES on recurrent myocardial infarction became statistically significant (RR = 1.82, *p* = 0.04, *I*^2^ = 42%). Except for the process, other sensitivity analyses did not show any relevant influence on the overall results, which further confirmed in direction and magnitude all the findings in the present study. Funnel plots were performed for all outcomes, and essential symmetries regarding overall stent thrombosis, TLR, recurrent myocardial infarction, and all-cause death were found, suggesting no publication bias in the meta-analysis.

Discussion {#S0013}
==========

The meta-analysis revealed that the second-generation EES significantly lowered the incidence of all-cause death compared with the first-generation SES and showed a tendency toward reducing recurrent myocardial infarction when compared with the PES. Moreover, the EES seemed likely to be more beneficial in lowering stent thrombosis than the overall first-generation DES. In contrast, the second-generation ZES were associated with an increased rate of stent thrombosis and TLR in comparison with the SES or the overall first-generation DES. Additionally, there were no significant differences in these outcomes between other comparisons of various DES.

Diabetes was a major predictor of restenosis secondary to exaggerated intimal hyperplasia in patients undergoing percutaneous coronary intervention (PCI) \[[@CIT0023]\]. Previous clinical studies and meta-analyses demonstrated the benefit of the first-generation DES (SES or PES) in reducing late luminal loss and the need for repeat revascularization in patients with diabetes mellitus compared with BMS. The newer second-generation DES, especially EES, appeared to be likely to improve further the clinical outcomes in unclassified coronary artery diseases \[[@CIT0024]--[@CIT0026]\]. However, the clinical value of the second-generation DES in diabetic patients remains unclear. A study by Sakata *et al*. indicated that diabetes mellitus and non-diabetes mellitus lesions showed a similar in-stent vessel response, which was detected using 3D intravascular ultrasound technique, regardless of the DES type \[[@CIT0027]\]. Of note, the drug used in the eluting stent, such as paclitaxel, could significantly attenuate the release of soluble vasoconstrictors (e.g. serotonin or thromboxane B~2~) that contribute to microvascular impairment. Such acute downstream vascular paralysis was beneficial in preventing the no-reflow phenomenon in patients undergoing stenting \[[@CIT0028]\]. Recently a mixed treatment comparison analysis demonstrated that among the currently used DES, EES was the most efficacious and safe in diabetic patients in terms of reducing the need for repeat revascularization and the incidence of stent thrombosis \[[@CIT0029]\]. The results support the overall clinical outcomes in the current study, which found lower rates of stent thrombosis, recurrent myocardial infarction, or all-cause death in patients treated with the EES.

There were relative differences among the DES in terms of efficacy and safety. In our analyses, the second-generation ZES were associated with higher rates of TLR and stent thrombosis compared with the SES or the overall first-generation DES. The SORT OUT III diabetes study indicated that treatment with ZES compared to SES resulted in a higher major adverse cardiac event rate in diabetic and nondiabetic patients \[[@CIT0019]\]. The inter-group difference was mainly driven by a higher rate of TLR owing to increased intima hyperplasia in the ZES group \[[@CIT0017]\]. Patients with diabetes develop a diffuse and rapidly progressive form of atherosclerosis, which increases the likelihood of requiring revascularization procedures \[[@CIT0030], [@CIT0031]\]. Moreover, diabetes promotes endothelial dysfunction and abnormalities in platelet activity and blood coagulation as well as increasing the risk of coronary thrombosis \[[@CIT0032]\]. However, in these specific subsets of patients with high risk of restenosis and stent thrombosis, the second-generation ZES showed inferiority in lowering these clinical outcomes to the first-generation DES, especially the SES. The finding was consistent with the results from a large-scale network meta-analysis on unselected coronary artery diseases \[[@CIT0033]\].

Methodologically, the use of a random-effect model, no publication bias, and relatively low statistical heterogeneities among the included trials might ensure the robustness of conclusions from the current study. Due to the limited study number and sample size, the results of the subgroup analyses were not solid enough, so they should be interpreted with caution. Therefore, more large-scale studies are required to further verify the findings and conclusions in the subgroup analyses of the current study.

In conclusion, this study has evaluated the current evidence from RCTs comparing clinical outcomes of the second- versus first-generation DES in patients with diabetes mellitus. Compared with the first-generation SES, the second-generation EES resulted in a significant decrease in all-cause mortality. The EES also showed a beneficial effect on reducing the incidence of reinfarction and stent thrombosis in comparison with the PES and the overall first-generation DES, respectively. Conversely, the use of the second-generation ZES was associated with increased risk of TLR and stent thrombosis compared with the first-generation DES, especially the SES. On the basis of these observations, the EES should be preferentially recommended in patients with diabetes mellitus while undergoing PCI.
